SLC5A2 and infection: With the extensive use of SGLT2 inhibitors, adverse events (AEs), such as infection-related AEs (Liu et al., 2017; Puckrin et al., 2018) and renal-related AEs (Perlman et al., 2017; Toyama et al., 2019) have been raised.